论文部分内容阅读
近年来肺癌发病率呈上升趋势,血清学肺癌标志物检测成为令人感兴趣的指标,目前一般应用血清癌胚抗原(CEA)和鳞状细胞癌抗原(SCC)为生化指标,其敏感性和特异性均欠佳.最近报道一种新的小细胞肺癌和非小细胞肺癌的标志物NSE,CYFRA21-1水平检测对小细胞和非小细胞肺癌的诊断,疗效评估和预后监测等都很有意义.本文通过对98例肺癌患者血清和胸水中的NSE,CYFRA21-1,CEA放射免疫分析,旨在探讨肺癌的发病机理,为临床诊断治疗提供依据.结果表明NSE在肺癌患者的血清中小细胞癌的阳性率为67.9%,与其它型肺癌相比较差异非常显著P<0.01;在肺癌患者的胸水中NSE水平的升高幅度明显高于非小
In recent years, the incidence of lung cancer has been on the rise, and detection of serological lung cancer markers has become an interesting indicator. Currently, serum carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC) are commonly used as biochemical markers, and their sensitivity and The specificity is not good. Recently, a new marker for small cell lung cancer and non-small cell lung cancer (NSE), CYFRA21-1, has been reported for the diagnosis of small cell and non-small cell lung cancer. Efficacy evaluation and prognosis monitoring are very good. Significance: The radioimmunoassay of NSE, CYFRA21-1 and CEA in serum and pleural fluid of 98 patients with lung cancer was used to investigate the pathogenesis of lung cancer and provide basis for clinical diagnosis and treatment. The results showed that NSE was in the serum of patients with lung cancer. The positive rate of cancer was 67.9%, which was significantly lower than that of other types of lung cancer (P<0.01). The increase of NSE levels in lung cancer patients’ pleural effusions was significantly higher than that of non-small cancers.